Immunophotonics, Inc. announced the initiation of recruitment and the dosing of its first patient in a clinical trial assessing safety and efficacy of its lead asset, IP-001, in multiple solid tumor indications.  This multinational clinical trial, denominated alternately as IP-IIO or INJECTABLE-1, is sponsored by Immunophotonics and will be enrolling patients for treatment of colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma.  The trial has been approved in Switzerland, the United Kingdom, and France.    Read more (Official Press Release)